AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes

British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare-type of the condition.